Medicover AB (publ)

OM:MCOV B Stock Report

Market Cap: SEK 30.6b

Medicover Valuation

Is MCOV B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MCOV B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 41.41
Fair Value
391.5% overvalued intrinsic discount
6
Number of Analysts

Below Fair Value: MCOV B (SEK203.5) is trading above our estimate of fair value (SEK41.41)

Significantly Below Fair Value: MCOV B is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MCOV B?

Key metric: As MCOV B is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MCOV B. This is calculated by dividing MCOV B's market cap by their current revenue.
What is MCOV B's PS Ratio?
PS Ratio1.3x
Sales€2.09b
Market Cap€2.74b

Price to Sales Ratio vs Peers

How does MCOV B's PS Ratio compare to its peers?

The above table shows the PS ratio for MCOV B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2x
DEDI Dedicare
0.3xn/aSEK 482.9m
EKTA B Elekta
1.4x6.9%SEK 25.2b
ATT Attendo
0.5x4.0%SEK 9.6b
VIMIAN Vimian Group
5.6x12.2%SEK 23.5b
MCOV B Medicover
1.3x11.8%SEK 30.6b

Price-To-Sales vs Peers: MCOV B is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (2x).

Price to Sales Ratio vs Industry

How does MCOV B's PS Ratio compare vs other companies in the European Healthcare Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
MCOV B 1.3xIndustry Avg. 0.6xNo. of Companies13PS00.61.21.82.43+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MCOV B is expensive based on its Price-To-Sales Ratio (1.3x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is MCOV B's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MCOV B PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.3x
Fair PS Ratio1.5x

Price-To-Sales vs Fair Ratio: MCOV B is good value based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (1.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MCOV B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 203.50
SEK 217.23
+6.7%
6.4%SEK 235.72SEK 189.86n/a6
Feb ’26SEK 206.00
SEK 214.74
+4.2%
7.2%SEK 236.52SEK 189.93n/a5
Jan ’26SEK 192.00
SEK 214.52
+11.7%
9.4%SEK 239.18SEK 178.92n/a5
Dec ’25SEK 175.80
SEK 214.38
+21.9%
10.2%SEK 239.13SEK 178.89n/a4
Nov ’25SEK 181.20
SEK 216.22
+19.3%
10.3%SEK 240.78SEK 180.11n/a4
Oct ’25SEK 185.40
SEK 212.20
+14.5%
9.7%SEK 237.74SEK 180.47n/a4
Sep ’25SEK 187.80
SEK 205.30
+9.3%
8.8%SEK 220.21SEK 179.80n/a3
Aug ’25SEK 187.40
SEK 207.63
+10.8%
9.3%SEK 222.20SEK 180.31n/a3
Jul ’25SEK 192.60
SEK 195.12
+1.3%
8.2%SEK 211.95SEK 173.48n/a3
Jun ’25SEK 196.80
SEK 199.13
+1.2%
8.2%SEK 220.14SEK 180.18n/a3
May ’25SEK 175.00
SEK 199.13
+13.8%
8.2%SEK 220.14SEK 180.18n/a3
Apr ’25SEK 138.00
SEK 190.26
+37.9%
5.4%SEK 203.56SEK 178.75n/a3
Mar ’25SEK 142.50
SEK 190.26
+33.5%
5.4%SEK 203.56SEK 178.75n/a3
Feb ’25SEK 170.60
SEK 201.25
+18.0%
9.0%SEK 220.52SEK 171.59SEK 206.004
Jan ’25SEK 150.10
SEK 201.25
+34.1%
9.0%SEK 220.52SEK 171.59SEK 192.004
Dec ’24SEK 143.20
SEK 213.90
+49.4%
10.6%SEK 236.19SEK 177.15SEK 175.804
Nov ’24SEK 126.80
SEK 223.16
+76.0%
11.0%SEK 248.27SEK 183.14SEK 181.204
Oct ’24SEK 143.70
SEK 223.16
+55.3%
11.0%SEK 248.27SEK 183.14SEK 185.404
Sep ’24SEK 155.40
SEK 223.16
+43.6%
11.0%SEK 248.27SEK 183.14SEK 187.804
Aug ’24SEK 157.50
SEK 219.66
+39.5%
10.5%SEK 240.64SEK 180.48SEK 187.404
Jul ’24SEK 163.70
SEK 224.27
+37.0%
12.0%SEK 251.43SEK 179.69SEK 192.604
Jun ’24SEK 167.70
SEK 219.29
+30.8%
10.8%SEK 244.17SEK 180.49SEK 196.804
May ’24SEK 169.10
SEK 214.01
+26.6%
9.7%SEK 232.10SEK 179.95SEK 175.004
Apr ’24SEK 168.00
SEK 205.00
+22.0%
15.5%SEK 227.89SEK 150.37SEK 138.004
Mar ’24SEK 178.80
SEK 200.94
+12.4%
15.1%SEK 225.58SEK 148.85SEK 142.504
Feb ’24SEK 179.30
SEK 178.04
-0.7%
19.4%SEK 236.97SEK 150.04SEK 170.604
Analyst Price Target
Consensus Narrative from 6 Analysts
SEK 217.23
Fair Value
6.3% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/20 12:23
End of Day Share Price 2025/02/20 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medicover AB (publ) is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
null nullABG Sundal Collier Sponsored
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB